Global
Our Story

Share the latest information

Our Story
News
2024-05-11
International Conference 及2024 BIO International Convention
Shanghai, China, May 11, 2024 - Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company dedicated to the research and development of innovative nanobody drugs, announced that Dr. Yakun
More
2024-05-11
International Conference 及2024 BIO International Convention
Shanghai, China, May 11, 2024 - Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company dedicated to the research and development of innovative nanobody drugs, announced that Dr. Yakun
More
2024-04-23
Novamab: LQ036 Completes The First Patient Dosing in Phase IIa Clinical Study
— The First Inhaled Biological Agent in China Provides A New Treatment Option for Asthma Patients
Shanghai, China, April 23, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced that its core product LQ036 (an IL-4Rα single-domain
More
2024-03-05
BioCon 2024- "Research Progress of Inhalable Nanobody Drug Therapy for Asthma" A Brief Discussion on Differentiated Development of Antibody Drugs and Clinical Progress of Novamab
Beijing time, March 6, 2024 (Wednesday), from 19:45 to 20:25, Dr. Siran Pei, the head of Translational Medicine and Clinical Development at Novamab, will participate in the pre-event live broadcast of
More
2024-02-29
Research Information - The development and scaling up of the production process of Novamab‘s anti TSLP Nanobody have reached an internationally leading level
Shanghai, February 29, 2024 - Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced the research progress on the development and scaling up
More
2024-02-22
Clinical Research Updatate - Novamab Announced the Latest Results of the Phase Ia Clinical Study on Inhaled TSLP Nanobody Drug LQ043H in Healthy Chinese Subjects
Shanghai, February 22, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nonobody drugs, announced today the results of the tolerance, safety, pharmacokine
More
2023-12-19
Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan
On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.
More
2023-11-13
The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!
Recently, Novamab and the team of Professor Zhang Xuyao/Ju Dianwen from the School of Pharmacy, Fudan University, jointly reported that the nanobody-drug conjugate (NDC) molecule targeting TROP2 has p
More
2023-09-26
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
More
2023-09-18
CDE approves IND application for LQ036 in the treatment of COPD
CDE approves IND application for LQ036 in the treatment of COPD ◇———A global leading Biotech in the  R&D of innovative Nanobody drugs———◇
More
2023-09-18
The first and only approved Nanobody drug in China contribute tothe performance growth of three listed companies!
What are other potential Nanobody drugs in China?
It’s very comforting to see the acceptance of Nanobody drugs in the field of biopharmaceuticals for  a biotech focusing on innovative Nanobody drugs, such as Novamab. Nanoantibodies have the adva
More
Total 54 123456